Pharmafile Logo

priority access

Meet us at ISPOR

Mtech Access are exhibiting at ISPOR in the US

After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

Mtech Access – Powered by Petauri™

- PMLiVE

AstraZeneca to acquire Fusion Pharmaceuticals in deal worth $2.4bn

The transaction includes a potential new treatment for metastatic castration-resistant prostate cancer

- PMLiVE

Merck’s pneumococcal vaccine candidate for adults shows promise in late-stage studies

V116 is designed to address the strains responsible for the majority of adult pneumococcal disease

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

AstraZeneca expands rare disease pipeline with $1.05bn Amolyt Pharma acquisition

The deal gives the company access to a late-stage candidate being evaluated for hypoparathyroidism

Market access and reimbursement in Canada – changes at CADTH

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...

Mtech Access – Powered by Petauri™

- PMLiVE

J&J and Protagonist’s JNJ-2113 shown to maintain skin clearance in plaque psoriasis

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disorder

- PMLiVE

AstraZeneca announces plans to invest £650m in UK to boost life sciences sector

The investment will also help to enhance public health protection and pandemic preparedness in the UK

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu not recommended by NICE for advanced breast cancer

Breast cancer is the most common form of cancer in the UK, accounting for over 55,000 cases every year

- PMLiVE

Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

- PMLiVE

Novartis shares positive results for spinal muscular atrophy gene therapy Zolgensma

The company said the results support the use of the one-time therapy in older and heavier children

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links